A disease with a few thousand patients — and the most expensive drug on Earth

Everyone asks the same question: if there are so few patients, why would a drug company bother? The answer is price. Rare-disease drugs are the most expensive in the world — not tens or hundreds of thousands a year like ordinary drugs, but $300,000 to over $3 million per year, or per dose. Look at the ranking of the world's most expensive drugs today: every one is a rare-disease drug, and almost all are single-shot gene therapies:

Lenmeldy, a gene therapy for metachromatic leukodystrophy (MLD) — a childhood neurological disease seen in about 1 in 40,000 — carries a price of $4.25 million per dose, the highest in the history of medicine. There's a logic to how the price climbs that high: if a single shot can cure a disease that would otherwise kill half of these children within 5 years, and replaces a lifetime of supportive care that could cost just as much — the payer (the state, the insurer) still has a reason to pay.

But the mechanism that makes this whole field possible isn't just price. It's a law: the US Orphan Drug Act of 1983, deliberately built to give companies a huge incentive to invest in diseases with too few patients to be worthwhile under normal terms.

These incentives flip the business equation. What used to be "few patients = not worth it" becomes "few patients + high price + 7-year exclusivity + de-risked by incentives = very much worth it." And it works — in 2024, nearly half (~47–52%) of the new drugs the FDA approved had orphan status, even though those diseases combined still affect only a small share of all patients.

Ordinary drugs make money on "volume" — a blood-pressure pill earns a tiny profit per pill, but you sell it to hundreds of millions of people, so it adds up to a fortune. Rare-disease drugs do the exact opposite: they make money on "value per head" — sold to a few thousand people, each paying the price of a luxury car. This is the equation investors have to understand cold.

The three legs of this equation prop each other up perfectly. The first is 7-year market exclusivity — once a drug gets orphan status, the FDA won't approve a competitor for the same disease for up to 7 years. That's a guarantee no one will undercut the price during payback. The second is a clearly defined patient base — because patients are few and concentrated in a handful of specialty medical centers, the company doesn't need a huge sales force like a blood-pressure drug. That keeps marketing costs low and margins fat.

The third leg is the fit with technology. Because most rare diseases come from a single broken gene, the problem can be defined precisely, in genetic letters. So gene therapy — which inserts a good gene to replace the bad one — or RNA drugs — which silence the faulty gene — can hit the target far more precisely than a complex disease like diabetes or heart disease, where many factors are tangled together. That's why "one shot and done" arrived in rare disease before anywhere else.

Rare Disease is a field that "cuts across" the other sub-themes of Biotech & Genomic Medicine rather than being a technology of its own. Because it's defined by market, not by how the drug is made — one rare disease might be treated with gene therapy, another with an RNA drug, another with a replacement protein. They all meet at the same point: "few patients, high price, orphan privileges."

• The main tool is gene therapy and gene editing: Single-gene rare diseases are the "dream test bed" for gene therapy, because you know exactly which gene is broken. The world's most expensive drugs — Zolgensma (SMA), Elevidys (DMD), Hemgenix (hemophilia) — are all gene therapies for rare diseases
• The sidekick is RNA drugs: for diseases where you need to "switch off" a faulty gene rather than "insert" a good one — like Alnylam's RNAi drugs, which earn money from rare genetic diseases such as hATTR amyloidosis
• The opposite of Biosimilars: these two are the two poles of Biotech — biosimilars fight to undercut the price of off-patent mass-market drugs, while rare disease is the drug with almost no competitor and the highest price. One side is "make drugs cheaper," the other is "the most expensive drug"
• Shares a base with Plasma-Derived & Blood Products: many drugs for rare blood disorders (hemophilia, immune deficiency) come from separating proteins out of plasma — among the very first rare diseases, before the gene-therapy era

In the wider megatrend view, rare disease leans more and more on AI — because few patients means little trial data. So AI steps in to help find drug targets, design trials that need fewer patients, and diagnose rare diseases that used to take years. And as aging societies grow, several slow-onset genetic diseases climb in demand too.

Rare disease has become one of the hottest battlegrounds in pharma. The global orphan-drug market was about $190–240 billion in 2024 (figures vary by source), and it's expected to grow at a CAGR of roughly 10–12% to $450–690 billion by 2032–2035 — clearly faster than the overall drug market, because every big company is turning toward "high-priced drugs with almost no competitor."

But the example that teaches this best is Vertex Pharmaceuticals — a company that built an entire empire out of a single rare disease: cystic fibrosis (CF), a genetic disease that clogs the lungs and organs with thick mucus. Vertex developed a class of drugs called "CFTR modulators" that fix the root cause — the broken protein made by the CFTR gene — and built a near-total monopoly in this disease worldwide.

ภาพประกอบ (vertex.png)

In 2024, Vertex earned $11 billion (up 12%), almost all from its CF drug class, and set a 2025 target of $11.75–12 billion. What's remarkable is that the company launched its 5th CFTR modulator (ALYFTREK, a once-a-day pill) in 2025 — moving existing patients onto a better drug and extending the monopoly even further. This is the textbook for building the most durable rare-disease franchise in the business.

Beyond Vertex, the arena is full of players focused specifically on rare disease. On the RNA-drug side, Alnylam earned $1.6 billion in 2024 (up 33%) and is targeting over $2 billion in 2025. On the gene-therapy and replacement-protein side, BioMarin, Ultragenyx, and Sarepta each stake out specific groups of genetic diseases. Take a look at the main players in this arena:

The clearest first direction is that the era of "one shot, full cure" is genuinely opening up. Rare diseases used to be treated with drugs you take for life (replacement proteins injected every week). But gene therapy changes the game to "pay once, cured" — Lenmeldy, Zolgensma, and Hemgenix are the first wave, and there are still thousands of rare diseases waiting for this technology. Every time the cost of making a gene therapy drops, a disease that was once "too small to be worth it" becomes a worthwhile target.

The second direction is going deeper into the "even rarer" (ultra-rare) diseases — ones with only a few hundred, or even a few dozen, patients worldwide. As AI cuts the cost of finding drug targets and designing trials that need fewer patients, companies start daring to invest in smaller and smaller diseases. Some go as far as making a custom drug (n-of-1) for a single patient.

The third direction is spreading out from the US. Europe and Japan have their own orphan-drug incentive laws, and Asian markets are catching up. Giants that never cared about rare disease — AstraZeneca, Novartis, Takeda — are all setting up dedicated rare-disease divisions, because it's the highest-margin, least-competitive source of revenue left.

This beautiful picture has a bigger structural crack than you'd think — and almost all of it comes back to one word: price.

The first risk is the payer pushback now building up. Insurers and governments used to pay for expensive rare-disease drugs because they figured "few patients, so the total budget isn't huge." But as orphan drugs come out more often every year, total cost is starting to hit a ceiling. Today, specialty drugs (including orphan) make up less than 5% of prescriptions but eat nearly 50% of the drug budget of private payers in the US — a ratio that's making payers ask harder whether a multi-million-dollar shot is really "worth it."

The second risk comes from the very nature of a patient base that's too small. When there are only a few thousand patients, trials are hard to run — you can't find enough patients to enroll, so the safety data is thinner than for an ordinary drug. And when a drug reaches the market and a side effect no one saw in the small group shows up, the stock swings hard. The case of Sarepta and its gene therapy Elevidys hitting safety problems in 2025 is a lesson that "one shot and done" comes with a risk that can also be done with fast.

The third risk is the politics of drug pricing. When the public eye fixes on "a $4 million-a-shot drug," it becomes an easy political target — even though rare disease is really only a small slice of total drug spending. But the shocking-looking numbers keep it a fixture in the drug-price debate, and in 2025 there were calls to review whether the Orphan Drug Act's incentives are "too generous." If those incentives get cut back, the whole equation we've described changes.

In short: rare disease is one of the most beautiful corners of the drug industry — where the most advanced science (gene therapy) meets the most genuine need (children who never had a treatment), and the economics that keep it alive are remarkably clever. But it stands on a delicate balance: between "a price high enough to motivate invention" and "a price so high society can't bear it" — and that line is the real battleground of the decade ahead.